Merck & Co., Inc. - Net Worth and Insider Trading
Merck & Co., Inc. Net Worth
The estimated net worth of Merck & Co., Inc. is at least $29 Million dollars as of 2024-04-27. Merck & Co., Inc. is the 10% Owner of NGM Biopharmaceuticals Inc and owns about 12,955,016 shares of NGM Biopharmaceuticals Inc (NGM) stock worth over $20 Million. Merck & Co., Inc. is the 10% Owner of Sutro Biopharma Inc and owns about 2,723,509 shares of Sutro Biopharma Inc (STRO) stock worth over $9 Million. Merck & Co., Inc. is also the 10% Owner of Harpoon Therapeutics Inc and owns about 1,000 shares of Harpoon Therapeutics Inc (HARP) stock worth over $23,010. Details can be seen in Merck & Co., Inc.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Merck & Co., Inc. has not made any transactions after 2024-03-11 and currently still holds the listed stock(s).
Transaction Summary of Merck & Co., Inc.
Merck & Co., Inc. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Merck & Co., Inc. owns 7 companies in total, including Arqule Inc (ARQL) , NGM Biopharmaceuticals Inc (NGM) , and Sutro Biopharma Inc (STRO) among others .
Click here to see the complete history of Merck & Co., Inc.’s form 4 insider trades.
Insider Ownership Summary of Merck & Co., Inc.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ARQL | Arqule Inc | 2019-12-06 | 10 percent owner |
| NGM | NGM Biopharmaceuticals Inc | 2019-04-08 | 10 percent owner |
| STRO | Sutro Biopharma Inc | 2018-10-01 | 10 percent owner |
| VYNE | VYNE Therapeutics Inc | 2018-01-24 | 10 percent owner |
| OPGN | OpGen Inc | 2015-07-14 | 10 percent owner |
| BGNE | BeiGene Ltd | 2016-02-02 | 10 percent owner |
| OGN | Organon & Co | 2021-05-07 | 10 percent owner |
Merck & Co., Inc. Latest Holdings Summary
Merck & Co., Inc. currently owns a total of 3 stocks. Among these stocks, Merck & Co., Inc. owns 12,955,016 shares of NGM Biopharmaceuticals Inc (NGM) as of April 8, 2019, with a value of $20 Million and a weighting of 68.12%. Merck & Co., Inc. owns 2,723,509 shares of Sutro Biopharma Inc (STRO) as of October 1, 2018, with a value of $9 Million and a weighting of 31.8%. Merck & Co., Inc. also owns 1,000 shares of Harpoon Therapeutics Inc (HARP) as of March 11, 2024, with a value of $23,010 and a weighting of 0.08%.
Latest Holdings of Merck & Co., Inc.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| NGM | NGM Biopharmaceuticals Inc | 2019-04-08 | 12,955,016 | 1.54 | 19,950,725 |
| STRO | Sutro Biopharma Inc | 2018-10-01 | 2,723,509 | 3.42 | 9,314,401 |
| HARP | Harpoon Therapeutics Inc | 2024-03-11 | 1,000 | 23.01 | 23,010 |
Holding Weightings of Merck & Co., Inc.
Merck & Co., Inc. Form 4 Trading Tracker
According to the SEC Form 4 filings, Merck & Co., Inc. has made a total of 0 transactions in NGM Biopharmaceuticals Inc (NGM) over the past 5 years. The most-recent trade in NGM Biopharmaceuticals Inc is the acquisition of 4,121,683 shares on April 8, 2019, which cost Merck & Co., Inc. around $66 Million.
According to the SEC Form 4 filings, Merck & Co., Inc. has made a total of 0 transactions in Sutro Biopharma Inc (STRO) over the past 5 years. The most-recent trade in Sutro Biopharma Inc is the acquisition of 666,666 shares on October 1, 2018, which cost Merck & Co., Inc. around $10 Million.
According to the SEC Form 4 filings, Merck & Co., Inc. has made a total of 1 transactions in Harpoon Therapeutics Inc (HARP) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Harpoon Therapeutics Inc is the acquisition of 21,397,205 shares on March 11, 2024, which cost Merck & Co., Inc. around $492 Million.
Insider Trading History of Merck & Co., Inc.
- 1
Merck & Co., Inc. Trading Performance
GuruFocus tracks the stock performance after each of Merck & Co., Inc.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Merck & Co., Inc. is -26.09%. GuruFocus also compares Merck & Co., Inc.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Merck & Co., Inc. within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Merck & Co., Inc.'s insider trading performs compared to the benchmark.
Performance of Merck & Co., Inc.
Average Return
-22.71%
Outperforming Transactions
0%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -13.55 | -26.09 | -28.78 | -22.71 | 6.3 | 4.82 |
| Relative Return to S&P 500(%) | -10.12 | -20.33 | -27.76 | -20.47 | -6.92 | -10.14 |
Merck & Co., Inc. Ownership Network
Ownership Network List of Merck & Co., Inc.
Ownership Network Relation of Merck & Co., Inc.
Merck & Co., Inc. Owned Company Details
What does Arqule Inc do?
Who are the key executives at Arqule Inc?
Merck & Co., Inc. is the 10 percent owner of Arqule Inc. Other key executives at Arqule Inc include director & Chief Executive Officer Paolo Pucci , CFO and Treasurer Marc Schegerin , and See Remarks Brian Schwartz .
Arqule Inc (ARQL) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Arqule Inc (ARQL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Arqule Inc (ARQL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Arqule Inc (ARQL)'s detailed insider trading history can be found in Insider Trading Tracker table.
Arqule Inc Insider Transactions
Merck & Co., Inc. Mailing Address
Above is the net worth, insider trading, and ownership report for Merck & Co., Inc.. You might contact Merck & Co., Inc. via mailing address: 2000 Galloping Hill Road, Kenilworth Nj 07033.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
